Chengdu Kanghong Pharmaceutical Group Co., Ltd

Total Valuation

Chengdu Kanghong Pharmaceutical Group Co., Ltd carries a market capitalization of 21.48B, placing it among publicly traded companies globally. Its enterprise value stands at 20.94B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Chengdu Kanghong Pharmaceutical Group Co., Ltd currently has 921.30M shares outstanding.

Valuation Ratios

Chengdu Kanghong Pharmaceutical Group Co., Ltd trades at a trailing price-to-earnings ratio of 21.93. The price-to-sales ratio is 5.84, and the price-to-book ratio stands at 4.26.

Enterprise Valuation

On an enterprise value basis, Chengdu Kanghong Pharmaceutical Group Co., Ltd trades at an EV/EBITDA multiple of 15.74 and an EV/FCF ratio of 132.46. The EV/Sales ratio of 4.54 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 15.74 provides insight into valuation relative to core operating earnings.

Financial Position

Chengdu Kanghong Pharmaceutical Group Co., Ltd maintains a current ratio of 10.26, meaning it holds 10.3x the short-term assets needed to cover near-term liabilities.

Financial Efficiency

Chengdu Kanghong Pharmaceutical Group Co., Ltd posts a return on equity of 20.54 and a return on invested capital of 13.59.

Taxes

Over the trailing twelve months, Chengdu Kanghong Pharmaceutical Group Co., Ltd has paid 175.37M in income taxes, reflecting an effective tax rate of 12.64.

Stock Price Statistics

Chengdu Kanghong Pharmaceutical Group Co., Ltd's stock has declined approximately -21.11675% over the past 52 weeks. The 50-day moving average sits at 21.95, while the 200-day moving average is 28.56.

Income Statement

Over the trailing twelve months, Chengdu Kanghong Pharmaceutical Group Co., Ltd generated 4.61B in revenue and converted that into 1.23B in net income, yielding earnings per share of 1.30. EBITDA reached 1.33B, while operating income came in at 1.33B.

Balance Sheet

Chengdu Kanghong Pharmaceutical Group Co., Ltd holds 6.00B in cash and equivalents against 3.73M in total debt, resulting in a net debt position of -3.33B. Total book value stands at 6.32B, with working capital of 5.99B providing operational flexibility.

Cash Flow

After subtracting -158.09M in capital expenditures, free cash flow totaled -158.09M - equivalent to -0.17 per share.

Margins

Chengdu Kanghong Pharmaceutical Group Co., Ltd operates with a gross margin of 89.61, reflecting its pricing power and cost economics. The operating margin of 28.85 and net profit margin of 26.64 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

Chengdu Kanghong Pharmaceutical Group Co., Ltd's most recent stock split took place on June 6, 2019 with a 10:13 split ratio.

Scores

Chengdu Kanghong Pharmaceutical Group Co., Ltd posts an Altman Z-Score of 26.25, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.